Navigation Links
Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
Date:10/22/2008

- Updated Preliminary Results Presented at 20th EORTC-NCI-AACR Symposium -

SOUTH SAN FRANCISCO, Calif. and GENEVA, Oct. 22 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced positive incremental data from its randomized, controlled Phase 2 clinical trial of picoplatin in patients with metastatic colorectal cancer (CRC). The expanded and updated results continue to indicate that picoplatin, given once every four weeks in combination with 5-fluorouracil and leucovorin (FOLPI), is associated with less frequent and severe neurotoxicity than oxaliplatin given in combination with 5-fluorouracil and leucovorin in the modified FOLFOX-6 regimen (FOLFOX). In addition, results continue to suggest that both regimens have similar anti-tumor activity in first-line metastatic CRC.

"Picoplatin appears to be an active platinum in colorectal cancer without the neurotoxicity of the other active platinum agents," said Richard Goldberg, M.D., associate director of clinical research for the University of North Carolina Comprehensive Center and physician-in-chief of the N.C. Cancer Hospital. Dr. Goldberg also is a member of Poniard's Clinical Advisory Board. "These early results may support a Phase 3 trial."

The data were presented in a poster session (abstract #210/poster #210) during the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer" in Geneva, Switzerland. Picoplatin, the Company's lead product candidate, is a new generation platinum chemotherapy agent with the potential to become a platform product addressing multiple indications, combinations and formulations for the treatment of multiple solid tumor indications.

Phase 2 CRC Trial
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... PARK, Calif. , July 24, 2014 /PRNewswire/ ... company in the emerging field of regenerative medicine, ... webcast of a presentation to investors on Tuesday, ... p.m. PDT.  The presentation will include an overview ... To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics ...
(Date:7/24/2014)... of Engineering at the University of Delaware, is ... in energy engineering, environmental sustainability and electronics. , ... rock with a well-defined, crystalline structure. At the ... decided that zeolites can separate molecules with size ... (one-tenth of a nanometer), making them useful to ...
(Date:7/24/2014)... 24, 2014 SRI International has been awarded ... Institute of Allergy and Infectious Diseases (NIAID), part of ... of potential therapies for HIV infection and AIDS. The ... and AIDS and the complications and opportunistic infections associated ... sexual transmission of HIV. According to ...
(Date:7/24/2014)... July 24, 2014 WIRB-Copernicus Group ® ... and ethical review services for clinical research, announced ... a division of Richmond, VA ... biosafety and biosecurity consulting firm in ... WCG,s biosafety division – WCG Biosafety™ – will ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4University of Delaware researcher describes new approach for creating organic zeolites 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3
... German . The heat which occurs in ... even a problem. On the contrary: It could be used ... more efficiently! These are two of the several potential applications ... (PTB). This so-called "thermoelectric voltage" may well be very interesting ...
... Spherix Incorporated (NASDAQ: SPEX ) ... diabetes, metabolic syndrome and atherosclerosis, and providers of ... biotechnology and pharmaceutical companies -- today announced that ... dyslipidemia in new studies of apolipoprotein E-deficient mice ...
... Oct. 24, 2011 Reaction Biology Corporation ("RBC"), ... services in epigenetics, today announced the rollout of ... research. RBC,s initial offerings will emphasize the histone ... has been no previous commercial source. ...
Cached Biology Technology:Magnetic nanoswitch for thermoelectric voltages 2Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight 2Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight 3Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight 4Reaction Biology Launches Recombinant Methyltransferase Line 2
(Date:7/25/2014)... scars on this false-color image from the Terra satellite show ... rash of wildfires in Eastern Russia. The burn scars ... background. The wildfires have broken across the remote parts ... this false-color image from the MODIS instrument, it is ... that continue. Two recent image features noted below show the ...
(Date:7/25/2014)... the International Journal of Cancer earlier this ... based on findings showing successful reduction in the risk ... of cells in the cervix. , The findings ... cells, or SCJ cells. These cells reside in the ... of cervical cancer. A research team co-led by Christopher ...
(Date:7/25/2014)... and Diabetes increasingly consume the healthcare community ... attention. , To address the worldwide ... low-and middle-income countries, global leaders in diabetes, ... in diabetes prevention and development of diverse ... text. , This book on "Global ...
Breaking Biology News(10 mins):Clearing cells to prevent cervical cancer 2What constitutes an effective response to the global 'diabesity' tsunami? 2
... highways or drive down any city street this ... manicured beds of flowers maintained by community volunteers ... gardens are taking root. Aside from the ... including landscaping and gardens, can help drivers reduce ...
... University doctoral student Jennifer Smith has shed new light on ... hunt for their food alone. In a paper ... a student in MSU,s Department of Zoology, shows that while ... cooperative societies, they also realize that venturing on their own ...
... 28, 2008The 2008 American Society for Microbiology (ASM) ... being presented to Stephen C. Edberg, Professor, Department ... School of Medicine, and Director, Clinical Microbiology Laboratory, ... this award recognizes a distinguished scientist for research ...
Cached Biology News:New roadside beautification concept studied 2Spotted hyenas can increase survival rates by hunting alone 2American Society for Microbiology honors Stephen C. Edberg 2
... ESGRO Complete Derivation Kit is intended ... cells from delayed blastocysts in serum-free ... Clonal Grade ... Blastocyst Incubation Medium Trypsin Solution ...
AedestaTM Animal Organ/Tissue Perfusion Soln....
RAT ANTI MOUSE JAM-2 Immunogen: Recombinant soluble JAM-2...
casein kinase 2, alpha 1 polypeptide, transcript variant 2, mRNA (cDNA clone MGC:15232 IMAGE:4121882), complete cds...
Biology Products: